Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.56 |
| ▸ | ESR1 | P03372 | 5/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14944879 | 0.84 | ESR1 (0.53) | ESR2ESR1 | |
| SCHEMBL4187049 | 0.83 | GABRA1 (0.47) | ESR2ESR1GABRA1GABRB2TYR | |
| SCHEMBL9734205 | 0.83 | GABRA1 (0.50) | ESR2ESR1GABRA1GABRB2TYR | |
| SCHEMBL1402200 | 0.81 | TYR (0.58) | GABRA1GABRB2TYR | |
| SCHEMBL29109661 | 0.80 | TYR (0.53) | ESR2ESR1NR3C1PGRNR3C2 | |
| SCHEMBL26379080 | 0.80 | ESR2 (0.49) | ESR2ESR1NR3C1PGRNR3C2 | |
| SCHEMBL13802284 | 0.80 | ESR2 (0.49) | ESR2ESR1NR3C1PGRNR3C2 | |
| SCHEMBL6926371 | 0.79 | ESR2 (0.51) | ESR2ESR1NR3C1PGRNR3C2 | |
| SCHEMBL28820010 | 0.79 | ESR1 (0.51) | ESR2ESR1NR3C1PGRNR3C2 | |
| SCHEMBL3031236 | 0.78 | KDM4E (0.47) | GABRA1GABRB2NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3359596-B1 | PHOSPHATE ESTER COMPOSITION AND USE | SASOL USA CORP (US) | 2025-05-07 | — | — | EP | claimed |
| CN-108291053-B | Phosphate ester composition and use | 萨索尔（美国）公司 | 2020-10-16 | — | — | CN | claimed |
| US-10544173-B2 | Phosphate ester composition and use | SASOL (USA) CORPORATION (US) | 2020-01-28 | — | — | US | claimed |
| US-20180273556-A1 | Phosphate Ester Composition and Use | SASOL USA CORP (US) | 2018-09-27 | — | — | US | claimed |
| WO-2017062557-A1 | PHOSPHATE ESTER COMPOSITION AND USE | SASOL (USA) CORPORATION (US) | 2017-04-13 | — | — | WO | claimed |
| US-4670494-A | BLEND WITH CHLORINATED POLYVINYL CHLORIDE, MOLYBDENUM, ALUMINA AND ISODECYL DIPHENYL PHOSPHATE/ | GARY CHEMICAL CORP. (US) | 1987-06-02 | — | — | US | claimed |
| EP-3359596-B1 | PHOSPHATE ESTER COMPOSITION AND USE | SASOL USA CORP (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-117157053-A | Oral care composition | 一丸自然美健有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | ERASCA, INC. | 2021-09-23 | — | — | US | disclosed |
| CN-108291053-B | Phosphate ester composition and use | 萨索尔（美国）公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10544173-B2 | Phosphate ester composition and use | SASOL (USA) CORPORATION (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180273556-A1 | Phosphate Ester Composition and Use | SASOL USA CORP (US) | 2018-09-27 | — | — | US | disclosed |
| WO-2017062557-A1 | PHOSPHATE ESTER COMPOSITION AND USE | SASOL (USA) CORPORATION (US) | 2017-04-13 | — | — | WO | disclosed |
| CN-101817713-B | Preparation method of 2, 2'-biphenyl diphenol and derivatives thereof | BEIJING OKEANOS TECHNOLOGY CO LTD | 2013-06-12 | — | — | CN | disclosed |
| CN-101817713-A | Preparation method of 2, 2'-biphenyl diphenol and derivatives thereof | BEIJING OKEANOS TECHNOLOGY CO LTD | 2010-09-01 | — | — | CN | disclosed |
| US-20090022462-A1 | FIRE RESISTANT JACKET COMPOSITION FOR ELECTRICAL COAXIAL AND FIBER OPTIC CABLE | POLYMER PRODUCTS COMPANY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273556-A1 | Phosphate Ester Composition and Use | PFKFB2, F12, PFKFB1 | ESR2 196/4885ESR1 205/4885GABRA1 2409/4885 |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | SDHB, CCNI, SDHA | ESR2 1457/4885ESR1 1755/4885GABRA1 1169/4885 |
| US-10544173-B2 | Phosphate ester composition and use | PFKFB2, F12, PFKFB1 | ESR2 196/4885ESR1 205/4885GABRA1 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.